PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12069236

Characterization of a cross-reactive electronic nose with vapoluminescent array elements.

Steven M Drew·Daron E Janzen·Kent R Mann
View original source ↗Export metadata ↓

Abstract

A three-channel cross-reactive sensor array based on vapoluminescent platinum(II) double salt materials has been characterized. Two arrays were studied, one consisting of [Pt(CN-cyclododecyl)4][Pt(CN)4] (1), [(phen)Pt(CN-cyclohexyl)2][Pt(CN)4] (2), and [Pt(CN-n-tetradecyl)4][Pt-(CN)4] (3) materials, where phen = 1,10-phenanthroline, and a second array that has compound 3 replaced by the mixed double salt material [(phen)Pt(CN-cyclododecyl)Cl)]2[(phen)Pt(CN-cyclododecyl)2]2[Pt(CN)4]3 (4). Compounds 2, 3 and 4 are characterized here for the first time. Inclusion of solvent vapors into these materials often leads to dramatic shifts in their solid-state absorption and luminescence spectra. In these studies the arrays were exposed to a set of 10 test solvent vapors to determine the ability of each cross-reactive array to give reproducible vapoluminescent spectra characteristic of each solvent vapor. It was discovered that temperature programming between solvent vapor exposures greatly improved the reproducibility of the luminescence spectra obtained. A statistical analysis of three-dimensional resolution factors between pairs of solvent clusters in principal component space supported this assertion. The success of the temperature programming protocol was limited by the thermal stability and the sensitivity to low background water vapor levels of some platinum(II) double salt materials. The ability of the cross-reactive sensor array to differentiate between two different solvent vapors over a large concentration range was also investigated. Acetone and methanol were found to occupy two distinct regions of the three-dimensional principal component space. Detection limits for acetone and methanol were estimated from the principal component analysis as 75 and 6 g/m3, respectively.

Explore related subjects

Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Steven M Drew, Daron E Janzen, Kent R Mann. 2002-06-01. Characterization of a cross-reactive electronic nose with vapoluminescent array elements.. https://doi.org/10.1021/ac011255d

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗